Method for constructing, packaging and screening recombinant oncolytic vaccinia virus by using fluorescent gene and loxp-CRE system and application of recombinant oncolytic vaccinia virus
Through the construction and packaging of fluorescent genes and loxp-CRE systems, the problem of low efficiency in construction and screening of recombinant viruses in the existing technology is solved, and the efficient construction of multi-targeted recombinant viruses is achieved, and the ability to treat tumors is improved. Evaluate.
Patent Information
- Application Number
- CN202410903133.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-08
- Publication Date
- 2024-11-19
AI Technical Summary
The efficiency of constructing and screening of recombinant oncolytic vaccinia viruses in the prior art is low, which affects the study of its genetic characteristics and the evaluation of tumor cells' anti-tumor ability.
The recombinant oncolytic vaccinia virus was constructed and packaged by using fluorescent genes and loxp-CRE systems to construct and package screen the recombinant oncolytic vaccinia virus. By constructing multi-targeted recombinant viruses, including single-target, dual-targeted and triple-targeted recombinant vaccinia viruses, the virus has been improved to kill tumors. Cell and progeny replication capability.
It has achieved efficient construction and packaging screening of recombinant oncolytic vaccinia virus, provided new research ideas and technical foundations, and improved the evaluation efficiency of virus characteristics and tumor treatment capabilities.
Smart Images

Figure CN118979064A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method for constructing and packaging a recombinant oncolytic vaccinia virus carrying and utilizing a fluorescent gene and a loxp-CRE system and an application thereof, belonging to the technical field of molecular biology. Background Art
[0002] Vaccinia virus (VV) mainly replicates and assembles in the cytoplasm, fundamentally avoiding the behavior of viral DNA invading the cell nucleus and contaminating the host genome, making it a potential virus for oncolytic immunotherapy. Its application in tumor immunotherapy mainly depends on its biological characteristics and application history. It has a double-stranded DNA genome structure, can encode about 250 genes, and can accommodate up to 50kb of exogenous genes. Its huge viral structure provides more selection space and transformation potential for carrying exogenous genes.
[0003] Vaccinia virus has four special forms of viral particles, including internal mature virus (IMV), internal enveloped virus (IEV), cell-associated enveloped virus (CEV) and external enveloped virus (EEV). Among them, EEV has unique advantages in long-distance transmission and in vivo diffusion in the host, with fast transmission speed and stronger resistance to neutralizing antibodies compared with IMV. Studies have shown that vaccinia virus is an improved virus with anti-tumor effect, which mainly exerts anti-tumor effect by activating and regulating immune cells and long-term anti-tumor immune response. For example: VVLΔTKΔN1L-mIL21 can effectively activate CD4+T cells and improve mouse survival rate in mouse colon cancer tumor model after treatment, while significantly increasing CD4+ and CD8+T cell concentrations in colon cancer tumor model and regulating tumor immune microenvironment. VVLΔTKΔN1L-mIL21 prevents the recurrence of CMT93 tumors by inducing the formation of neutral memory T cells and maintains long-term anti-tumor immune response. VG9-IL-24 also induces apoptosis by activating apoptotic signaling pathways, such as activating PKR (protein kinase R), thereby phosphorylating the downstream target p38 MAPK (mitogen-activated protein kinase), further stimulating the MAPK signaling pathway, and inhibiting the phosphorylation of STAT3 (signal transducer and activator 3).
[0004] It can be seen that oncolytic vaccinia virus, as a new type of tumor treatment, shows good therapeutic effects in the treatment of malignant tumors. It has high tumor targeting and low side effects. It can stimulate tumor-specific and non-specific immune responses to induce tumor cell apoptosis, thereby destroying the tumor. Adding specific genes (such as cytokines, immune checkpoints, etc.) to the oncolytic vaccinia virus genome can construct recombinant oncolytic vaccinia virus, further improve the tumor suppression ability, and enhance the treatment effect. Therefore, efficient screening of recombinant viruses is of great significance for basic research such as studying the genetic characteristics of vaccinia viruses and their anti-tumor ability against tumor cells. However, in current cancer research, the current conventional construction and screening methods are inefficient. Summary of the invention
[0005] In order to solve the above-mentioned problems of the prior art, the present invention provides a method for constructing and packaging and screening recombinant oncolytic vaccinia viruses using a fluorescent gene and a loxp-CRE system and its application, which has the technical characteristics of being able to efficiently construct, package and screen new oncolytic vaccinia viruses, thereby providing a technical basis for the study of the viral characteristics of oncolytic vaccinia viruses.
[0006] In order to achieve the above object, the present invention is implemented by the following technical solutions:
[0007] The present invention provides a method for constructing, packaging and screening a recombinant oncolytic vaccinia virus carrying a fluorescent gene and a loxp-CRE system, comprising the following steps:
[0008] Step 1): constructing a plasmid pBATK-EGFP carrying the EGFP gene, wherein the plasmid pBATK-EGFP is a de novo constructed plasmid, which uses the Western Reverse strain of vaccinia virus as a backbone and uses EGFP as a screening marker;
[0009] Step 2): construct a plasmid pX459-TK-gRNA carrying a TK-gRNA sequence, wherein the plasmid pX459-TK-gRNA uses a CRISPR / Cas9 plasmid as a template and carries a gRNA targeting the TK gene of the vaccinia virus genome; construct a plasmid px459-C11R-gRNA carrying a VGF gene C11R-gRNA sequence; construct a plasmid px459-B8R-gRNA carrying an IFN-γ gene B8R-gRNA sequence;
[0010] Step 3): constructing a plasmid pcDNA3.1-loxp-CRE carrying a loxp-CRE sequence, wherein the plasmid pcDNA3.1-loxp-CRE is based on pcDNA3.1 and has a loxp site and a CRE enzyme gene sequence inserted therein;
[0011] Step 4): Plasmid px459-TK-gRNA and plasmid pBATK-EGFP were transfected into HEK293A cells and infected with VV-WR oncolytic vaccinia virus, and after packaging, the recombinant oncolytic vaccinia virus VV-ΔT-EGFP carrying the EGFP gene and the TK gene was deleted, the recombinant oncolytic vaccinia virus VV-ΔV-EGFP carrying the EGFP gene and the C11R gene was deleted, and the recombinant oncolytic vaccinia virus VV-ΔB-EGFP carrying the EGFP gene and the B8R gene was deleted was obtained respectively;
[0012] Step 5): transfecting the pCDNA3.1-loxp-CRE described in step 3) into HEK293A cells, and infecting VV-ΔT-EGFP, VV-ΔV-EGFP or VV-ΔB-EGFP oncolytic vaccinia virus, and packaging to obtain recombinant oncolytic vaccinia viruses VV-ΔT, VV-ΔV and VV-ΔB in which the EGFP gene is deleted and the TK gene is deleted;
[0013] Step 6): using the recombinant oncolytic vaccinia viruses VV-ΔT, VV-ΔV and VV-ΔB obtained in step 5) as the base viruses, respectively, steps 4) and 5) are repeated to obtain dual-targeted recombinant oncolytic vaccinia viruses VV-ΔTV, VV-ΔVB and VV-ΔTB that simultaneously lack TK and VGF, simultaneously lack TK and B8R, and simultaneously lack VGF and B8R;
[0014] Step 7): Using the dual-targeted recombinant oncolytic vaccinia virus VV-ΔTV obtained in step 6) as the base virus, repeat the transfection of px459-B8R-gRNA and pCDNA3.1-loxp-CRE in steps 4) and 5) to obtain the triple-targeted recombinant oncolytic vaccinia virus VV-ΔTVB.
[0015] Preferably, the step 1) comprises the following sub-steps:
[0016] Step 1-1): perform high assurance PCR on pCB023-Ⅱ; amplify pCB-backbone; Step 1-2): perform high assurance PCR on pcDNA3.1-EGFP; amplify loxp EGFP; Step 1-3): seamlessly clone the pCB-backbone and loxpEGFP to obtain the pBATK-EGFP.
[0017] Preferably, the step 2) comprises the following sub-steps:
[0018] Step 2-1): synthesize TK-gRNA; Step 2-2): connect the TK-gRNA to px459 to obtain px459-TK-gRNA.
[0019] Preferably, the step 3) comprises the following sub-steps: step 3-1): synthesizing Cre-HA; step 3-2): connecting the Cre-HA to pcDNA3.1 to obtain pcDNA3.1-Cre-HA.
[0020] Preferably, the step 4) includes the following sub-steps: step 4-1): transfecting px459-TK-gRNA into HEK293A cells; step 4-2): infecting the HEK293A cells in step 4-1) with VV-WR oncolytic vaccinia virus; step 4-3): transfecting pBATK-EGFP into the HEK293A cells in step 4-2), and obtaining VV-ΔT-EGFP after culture.
[0021] Preferably, the step 5) comprises the following sub-steps: step 5-1): transfecting pcDNA3.1-Cre-HA into HEK293A cells; step 5-2): infecting the HEK293A cells in step 5-1) with VV-ΔT-EGFP, VV-ΔV-EGFP or VV-ΔB-EGFP oncolytic vaccinia virus, and obtaining single-targeted oncolytic vaccinia viruses VV-ΔT, VV-ΔV or VV-ΔB, dual-targeted recombinant oncolytic vaccinia viruses VV-ΔTV, VV-ΔVB, VV-ΔTB and triple-targeted recombinant oncolytic vaccinia viruses VV-ΔTVB after culture.
[0022] The single-targeted recombinant oncolytic vaccinia virus VV-ΔT, VV-ΔV or VV-ΔB, and the dual-targeted recombinant oncolytic vaccinia virus VV-ΔTV, VV-ΔVB, VV-ΔTB and the triple-targeted recombinant oncolytic vaccinia virus VV-ΔTVB constructed above have the ability to kill tumor cells comparable to or better than the wild-type virus VV-WR;
[0023] The above-constructed single-targeted recombinant oncolytic vaccinia viruses VV-ΔT, VV-ΔV or VV-ΔB, as well as the dual-targeted recombinant oncolytic vaccinia viruses VV-ΔTV, VV-ΔVB, VV-ΔTB and the triple-targeted recombinant oncolytic vaccinia virus VV-ΔTVB have comparable or better progeny replication ability in tumor cells than the wild-type virus VV-WR.
[0024] An application for constructing, packaging and screening recombinant oncolytic vaccinia viruses using a fluorescent gene and a loxp-CRE system, which is applied to products including drugs, pharmaceutical raw materials or targeted inhibitors.
[0025] Preferably, the medicament comprises an oncolytic vaccinia virus vaccine.
[0026] Preferably, the drug further comprises pharmaceutically acceptable excipients.
[0027] Preferably, the auxiliary material may be one or more of an osmotic pressure regulator, a lyoprotectant, a surfactant, a buffer, and an excipient.
[0028] Preferably, the primers for the high-fidelity PCR reaction in step 1-1) include: pCB-backbone F (SEQ ID NO: 1), having the following sequence: 5'-tcttttcaacgcctggcactg-3'; pCB-backbone R (SEQ ID NO: 2), having the following sequence: 5'-gtgaagtgtcccagcctgtttatc-3'.
[0029] The high-fidelity PCR reaction system in step 1-1) includes: KOD New buffer (5 μL), 2 mM dNTPs (5 μL), 25 mM MgSO4 (3 μL), upstream primer (1.5 μL), downstream primer (1.5 μL), template (2 μL), KOD enzyme (1 μL), and ddH2O to make up the volume to 50 μL.
[0030] The high-fidelity PCR reaction program in step 1-1) is: 94°C-96°C for 2-3 min; 96-98°C for 10-30 s, 55-60°C for 15-30 s, 65-70°C for 20-30 s, for a total of 35-40 cycles, and finally 68°C for 7 min.
[0031] Preferably, the primers for the high-fidelity PCR reaction in step 1-2 include:
[0032] The sequence of loxp EGFP F (SEQ ID NO: 3) is as follows:
[0033] 5'-gctgggacacttcacataacttcgtatagcatacattatacgaagttatATGGTGAGCAAGGGCGAG-3'; loxp EGFP R PCR (SEQ ID NO: 4) sequence is as follows:
[0034] 5'-gccaggcgttgaaaagactaCTTGTACAGCTCGTCCATGCC-3'.
[0035] The high-fidelity PCR reaction system in step 1-2) includes: KOD New buffer (5 μL), 2 mM dNTPs (5 μL), 25 mM MgSO4 (3 μL), upstream primer (1.5 μL), downstream primer (1.5 μL), template (2 μL), KOD enzyme (1 μL), and ddH2O to make up the volume to 50 μL.
[0036] The high-fidelity PCR reaction program in step 1-2) is: 94°C-96°C for 2-3 min; 96-98°C for 10-30 s, 55-60°C for 15-30 s, 65-70°C for 20-30 s, for a total of 35-40 cycles, and finally 68°C for 7 min.
[0037] In step 1-3), two PCR amplification products are first recovered by agarose gel electrophoresis, and then the two recovered products are connected by seamless cloning kit according to a preset molar mass ratio, and then the connection products are transformed into competent DH5α, cultured, and extracted to obtain plasmid pBATK-EGFP.
[0038] Preferably, the concentration of agarose gel is 0.5-2%, for example: 0.5%, 0.7%, 1.0%, 1.3%, 1.5%, 1.7%, 2.0%.
[0039] Preferably, the time of agarose gel electrophoresis is 20 to 35 min, for example: 20 min, 25 min, 30 min, 35 min.
[0040] Preferably, the molar mass ratio of the two rubber tapping recovery products is pCB-backbone:loxp EGFP=1:1.
[0041] Preferably, the ligation temperature of pCB-backbone and loxp EGFP is 40-55°C, such as 40°C, 43°C, 45°C, 47°C, 50°C, 52°C, 55°C.
[0042] Preferably, the ligation time of pCB-backbone and loxp EGFP is 10-20 min, for example, 10 min, 12 min, 15 min, 17 min, 20 min.
[0043] Preferably, the competent cells are DH5α.
[0044] Preferably, in step 2-1), the forward sequence of TK-gRNA TK gRNAF (SEQ ID NO: 5) is as follows: 5'-CACCGgtgtatgaaatgctttaagg-3'; the reverse sequence of TK-gRNA TK gRNAR (SEQ ID NO: 6) is as follows: 5'-AAACccttaaagcatttcatacacC-3'.
[0045] Preferably, the annealing reaction program of TK-gRNA in step 2-1) is: 90℃~100℃ 5~10min; 80℃~90℃ 5~10min, 70℃~80℃ 5~10min, 60℃~70℃ 5~10min, 50℃~60℃ 5~10min, 40℃~50℃ 5~10min, 30℃~40℃ 5~10min, 20℃~30℃ 5~10min, 10℃~20℃ 5~10min.
[0046] Preferably, in step 2-2), the pX459 plasmid is linearized by single restriction digestion with BbsI and then dephosphorylated.
[0047] Preferably, in step 2-2), the pX459 dephosphorylating enzyme is Fast AP.
[0048] Preferably, in step 2-2), the two genes are connected using 2×Ligation high ver.2 and transformed into competent cells, and px459-TK-gRNA is obtained after culture and extraction.
[0049] Preferably, the concentration of agarose gel is 0.5-2%, for example: 0.5%, 0.7%, 1.0%, 1.3%, 1.5%, 1.7%, 2.0%.
[0050] Preferably, the time of agarose gel electrophoresis is 20 to 35 min, for example: 20 min, 25 min, 30 min, 35 min.
[0051] Preferably, the competent cell is one of DH5α, TG1, Mach1-T1, and XL10-Gold, and more preferably DH5α.
[0052] Preferably, the transfection reagent for px459-TK-gRNA in step 4-1) can be lipo3000, lipo8000, or PEI, and PEI is more preferably used.
[0053] The ratio of the transfection reagent to px459-TK-gRNA in step 4-1) is 5:1, 4:1, 3:1, 2:1, and more preferably 4:1.
[0054] The transfection time in step 4-1) is 3-6 h, for example: 2 h, 3 h, 4 h, 5 h, 6 h.
[0055] Preferably, in step 4-2), the MOL of VV-WR is 0.1-10, for example 0.1, 0.5, 1, 2, 5, 10. In step 4-2), the infection time of VV-WR is 1-6h, for example 1h, 2h, 3h, 4h, 5h, 6h. In step 4-3), the transfection reagent of pBATK-EGFP can be selected from lipo3000, lipo8000, PEI, and PEI is further preferably selected. In step 3-3), the ratio of transfection reagent to pBATK-EGFP is 5:1, 4:1, 3:1, 2:1, and 4:1 is further preferably selected. In step 3-3), the transfection time is 3-6h, for example: 2h, 3h, 4h, 5h, 6h. In step 5-1), the transfection reagent of pcDNA3.1-Cre-HA can be selected from lipo3000, lipo8000, PEI, and PEI is more preferably selected. The ratio of transfection reagent to pcDNA3.1-Cre-HA in step 5-1) is 5:1, 4:1, 3:1, 2:1, and 4:1 is more preferably selected. The transfection time in step 5-1) is 3-6h, for example: 2h, 3h, 4h, 5h, 6h. In step 5-2), the MOL of VV-ΔT-EGFP is 0.1-10, for example 0.1, 0.5, 1, 2, 5, 10. In step 5-2), the infection time of VV-ΔT-EGFP is 1-6h, for example 1h, 2h, 3h, 4h, 5h, 6h.
[0056] Preferably, the osmotic pressure regulator includes sucrose, trehalose, mannitol, sorbitol. The lyophilization protectant includes trehalose and sucrose. The buffer includes histidine, citric acid, succinic acid, acetate or phosphate; the surfactant includes polysorbate 20, polysorbate 80, poloxamer 188 or polyethylene glycol 3350.
[0057] Beneficial effects: The method described in the present invention can be used to efficiently construct, package and screen new oncolytic vaccinia viruses, which not only provides new ideas and methods for the research on the packaging and screening of oncolytic vaccinia viruses, but also provides a technical basis for the study of the viral characteristics of oncolytic vaccinia viruses. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Figure 1 Schematic diagram of the method for constructing, packaging and screening recombinant oncolytic vaccinia viruses using fluorescent genes and loxp-CRE system;
[0059] Figure 2 The results of construction and identification of the oncolytic vaccinia virus single gene site deletion strains VV-ΔB, VV-ΔV, and VV-ΔT in Example 1;
[0060] Figure 3The results of construction and identification of the oncolytic vaccinia virus double gene site deletion strains VV-ΔBV, VV-ΔTV, and VV-ΔTB in Example 2;
[0061] Figure 4 The results of construction and identification of the oncolytic vaccinia virus triple gene site deletion strain VV-ΔBVT in Example 3;
[0062] Figure 5 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0063] Figure 6 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0064] Figure 7 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0065] Figure 8 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0066] Fig. 9 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0067] Fig.10 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0068] Fig.11 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0069] Fig.12 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0070] Fig.13 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0071] Fig.14 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0072] Fig.15 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0073] Fig.16 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0074] Fig.17 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0075] Fig.18 The results of the MTT method in Example 5 for detecting the cell survival rate of tumor cells after virus infection;
[0076] Fig.19 The following are the test results of the progeny replication ability of the three-site deletion strain of vaccinia virus in Example 6;
[0077] Fig. 20 The following are the test results of the progeny replication ability of the three-site deletion strain of vaccinia virus in Example 6;
[0078] Fig.21 The results of the sensitivity verification of vaccinia virus VV-ΔBVT-EC to IFN-γ in colon cancer cells in Example 7;
[0079] The experimental data of each group in the above figure were statistically analyzed using GraphPad Prism 9 software to compare the data differences between different groups. The experimental data are expressed in the form of mean ± SD. If p < 0.05, a significant difference is marked, where p < 0.05 is marked with *, p < 0.01 is marked with **, p < 0.001 is marked with ***, and p < 0.0001 is marked with ****. All experiments were repeated three times. Figure 5-11 In the figure, the dendrograms represent VV-ΔB, VV-ΔV, VV-ΔT, and VV-WR respectively; Figure 12-18 In the figure, the dendrograms represent VV-ΔTB, VV-ΔTV, VV-ΔBV, VV-ΔBVT, and VV-WR, respectively; Figure 19-20 In the figure, the triangle represents 1 mol VV-WR, and the square represents 1 mol VV-ΔBVT. DETAILED DESCRIPTION
[0080] The following is in conjunction with the instruction manual Figure 1-21 , the present invention is further illustrated, but the present invention is not limited to the following embodiments.
[0081] Many genes in the oncolytic vaccinia virus genome ensure the virus's targeting, replication, and tumor suppression abilities. At the same time, a large number of genes have limited effects when the virus is used as an oncolytic virus. These genes can be modified and altered to further improve the tumor treatment ability of oncolytic vaccinia virus.
[0082] The J2R gene expresses thymidine kinase (TK, T), which is differentially expressed in tumor cells and normal cells. Deleting it can improve the tumor targeting of oncolytic vaccinia virus during treatment. The C11R gene expresses viral growth factor (VGF, V), which regulates cell growth status by competing with epithelial growth factor (EGF) for EGF receptors. Deleting it can further improve the killing effect of oncolytic virus in tumor cells. The B8R (B) gene expresses IFN-γ receptor protein (IFN-γR), which competes with IFN-γ for receptor protein, evades the antiviral effect of IFN-γ, and thus escapes the attack of the body's immune system. Experiments have found that deleting this gene will not affect the virus's killing process in tumor cells, while reducing damage to normal cells.
[0083] At present, the technical research has not realized the construction and use of a triple-targeted oncolytic vaccinia virus with three genes of TK, VGF and IFN-γ receptor deleted at the same time as a vector, and no technician has successfully realized it. The present invention creatively uses the gene editing CRISPR / Cas9 method to efficiently screen oncolytic vaccinia viruses, reducing the contamination of wild-type viruses and the efficiency of screening.
[0084] Example 1 Construction of oncolytic vaccinia virus single gene site deletion strains VV-ΔB, VV-ΔV, and VV-ΔT
[0085] 1.1 Construction of plasmid pBAB8R-EGFP
[0086] 1.1.1 Obtaining B8R upstream and downstream fragments B8R-L and B8R-R
[0087] Primers were designed based on the upstream and downstream sequences B8R-L and B8R-R of the vaccinia virus B8R gene site. B8R-LF (SEQ ID NO: 8) has the following sequence: 5'-CCATCGATatgtataaaaaactaataacgtttt-3'; B8R-LR (SEQ ID NO: 9) has the following sequence: 5'-GGGCATGCggtgttgtttgt-3; B8R-RF (SEQ ID NO: 10) has the following sequence: 5'-CATATGggttaacgcccttataggctct-3; B8R-RR (SEQ ID NO: 11) has the following sequence: 5'-CGACGCGTtcaataaggagaagttgataatgcc-3.
[0088] The high-fidelity B8R-L and B8R-R sequences were isolated from the WR of the vaccinia virus genome. The specific PCR reaction process was as follows:
[0089] High-fidelity PCR reaction system: KOD New buffer (5μL), 2mM dNTPs (5μL), 25mM MgSO4 (3μL), upstream primer (1.5μL), downstream primer (1.5μL), template (2μL), KOD enzyme (1μL), and ddH2O to make up the volume to 50μL.
[0090] PCR reaction program: pre-denaturation at 94°C for 2 min, denaturation at 98°C for 10 s, annealing at 56°C for 30 s, extension at 68°C for 30 s, and extension at 68°C for 7 min after 35 cycles.
[0091] 1.1.2 Obtaining pBAB8R-EGFP
[0092] 1% agarose gel electrophoresis at 120v for 30min, and the two PCR amplification products B8R-L and B8R-R were recovered using a gel tapping recovery kit (Youkang Biological Product No.: YK00A2). The vectors pBATK-EGFP and B8R-L were double-digested with ClaⅠ and SphⅠ, and the two genes were connected using 2×Ligation high ver.2. The connection product was transformed into competent DH5α, spread on an LB solid plate containing ampicillin, and cultured at 37°C for 10-16h. The monoclonal plaque was picked and transferred to a liquid LB medium containing ampicillin, and cultured at 220rpm for 10-16h, and then the recombinant vector pBAB8R-EGFP-L was extracted using a plasmid extraction kit.
[0093] The vectors pBAB8R-EGFP-L and B8R-R were double-digested with NdeⅠ and MluⅠ, and the two genes were connected using 2×Ligation highver.2. The connected products were transformed into competent DH5α, spread on LB solid plates containing ampicillin, cultured at 37°C for 10-16h, picked monoclonal plaques, transferred to liquid LB culture medium containing ampicillin, and cultured at 220rpm for 10-16h. Then, the recombinant vector pBAB8R-EGFP was extracted using a plasmid extraction kit.
[0094] 1.2 Construction of plasmid px459-B8R-gRNA
[0095] 1.2.1 Synthesize B8R-gRNA;
[0096] The forward sequence of B8R-gRNA B8R gRNA F (SEQ ID NO: 12) was synthesized as follows: 5'-caccAAAATTATGGCATCAAGACG-3'; the reverse sequence of B8R-gRNA B8R gRNAR (SEQ ID NO: 13) was synthesized as follows: 5'-aaacCGTCTTGATGCCATAATTTT-3'.
[0097] The forward and reverse sequences of B8R-gRNA were annealed to form a double-stranded DNA structure. The annealing reaction program was: 90℃~100℃5~10min; 80℃~90℃5~10min, 70℃~80℃5~10min, 60℃~70℃5~10min, 50℃~60℃5~10min, 40℃~50℃5~10min, 30℃~40℃5~10min, 20℃~30℃5~10min, 10℃~20℃5~10min.
[0098] 1.2.2 Obtaining px459-B8R-gRNA
[0099] The pX459 plasmid was linearized using BbsI and the digestion product was dephosphorylated using the dephosphorylase Fast AP. The two genes were connected using 2×Ligation high ver.2 and the connected product was transformed into competent DH5α, spread on a solid LB plate containing ampicillin, cultured at 37°C for 10-16h, picked monoclonal plaques, transferred to liquid LB medium containing ampicillin, and cultured at 220rpm for 10-16h, and then the recombinant vector px459-B8R-gRNA was extracted using a plasmid extraction kit.
[0100] 1.3 Construction and packaging of VV-ΔB
[0101] 1.3.1 Obtaining VV-ΔB-EGFP
[0102] 2 μg of px459-B8R-gRNA plasmid extracted with endotoxin-free medium was diluted with PEI in a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, 6-well plate with fresh 10% FBS cell culture medium. Place in a 37 ° C 5% CO2 cell culture incubator, culture for 8 hours, discard the cell supernatant, replace with fresh 5% FBS cell culture medium, discard the cell supernatant after 24 hours, infect VV-WR oncolytic virus according to 1MOL thin layer, discard the virus liquid after 2 hours, extract 2μg pBAB8R-EGFP plasmid without endotoxin, according to the mass ratio of plasmid: PEI = 1:3, dilute and mix PEI with serum-free medium, and then slowly drip into the mixture of plasmid and serum-free medium, gently mix, and stand at room temperature for 15 minutes. After standing, add the mixture to a 6-well plate containing 3×105 / well HEK293A, and add fresh 10% FBS cell culture medium to the 6-well plate. Place the cells in a 37°C 5% CO2 cell culture incubator. After culturing for 8 hours, discard the cell supernatant and replace with fresh 5% FBS cell culture medium. Continue culturing for 3 days to observe cell lesions and fluorescence. After lesions, collect the supernatant and cells to obtain the first-generation virus P1, i.e., oncolytic vaccinia virus VV-ΔB-EGFP.
[0103] 1.3.2 Obtaining VV-ΔB
[0104] 2 μg of pcDNA3.1-Cre-HA plasmid extracted with endotoxin-free medium was diluted with PEI in a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, 6-well plate with fresh 10% FBS cell culture medium. Place in 37℃5% CO2 cell culture incubator, culture for 8 hours, discard the cell supernatant, replace with fresh 5% FBS cell culture medium, discard the cell supernatant after 24 hours, infect VV-ΔB-EGFP oncolytic virus according to 1MOL thin layer, discard the virus liquid after 2 hours, replace with fresh 5% FBS cell culture medium, continue to culture for 3 days, observe cell lesions and fluorescence, collect supernatant and cells after lesions, and obtain the first generation virus P1, i.e. oncolytic vaccinia virus VV-ΔB.
[0105] 1.4 Construction of plasmid pBAC11R-mCherry
[0106] 1.4.1 Obtaining C11R upstream and downstream fragments C11R-L and C11R-R
[0107] Primers were designed based on the upstream and downstream sequences C11R-L and C11R-R of the vaccinia virus C11R gene site. The sequence of C11R-LF (SEQ ID NO: 12) is as follows:
[0108] 5'-gtgccacctgacgtcatcgatCCACAGCAATAGATCGGATGATT-3';
[0109] The sequence of C11R-LR (SEQ ID NO: 13) is as follows:
[0110] 5'-atggataaaaaggcggcatgcCAGTGTGTGTTTATGACAAGATTGGG-3';
[0111] The sequence of C11R-RF (SEQ ID NO: 14) is as follows:
[0112] 5'-ccCATATGccttgaaaatgaatacagtgggtgg-3';
[0113] The sequence of C11R-RR (SEQ ID NO: 15) is as follows:
[0114] 5'-cgACGCGTgataataagcgtacgtgttctaattggg-3'.
[0115] The C11R-L and C11R-R sequences were obtained by high-fidelity PCR from the WR of the vaccinia virus genome. The specific PCR reaction process is as follows:
[0116] High-fidelity PCR reaction system: KOD New buffer (5μL), 2mM dNTPs (5μL), 25mM MgSO4 (3μL), upstream primer (1.5μL), downstream primer (1.5μL), template (2μL), KOD enzyme (1μL), and ddH2O to make up the volume to 50μL.
[0117] PCR reaction program: pre-denaturation at 94°C for 2 min, denaturation at 98°C for 10 s, annealing at 56°C for 30 s, extension at 68°C for 30 s, and extension at 68°C for 7 min after 35 cycles.
[0118] 1.4.2 Obtaining pBAC11R-EGFP
[0119] 1% agarose gel electrophoresis at 120v for 30min, and a gel tapping recovery kit (Youkang Biological Product No.: YK00A2) was used to recover the two PCR amplification products C11R-L and C11R-R. The vectors pBATK-EGFP and C11R-L were double-digested with ClaⅠ and SphⅠ, and the two gel tapping recovery products were connected at a molar mass ratio of pBATK-EGFP and C11R-L = 1:3 through a seamless cloning kit (Quanshijin, Product No.: CU101-01), 50°C for 15min, and then the connection product was transformed into competent DH5α, coated on an LB solid plate containing ampicillin, and cultured at 37°C for 10-16h, then a monoclonal plaque was picked and transferred to a liquid LB medium containing ampicillin, and cultured at 220rpm for 10-16h, and then the recombinant vector pBAC11R-EGFP-L was extracted using a plasmid extraction kit.
[0120] The vectors pBAC11R-EGFP-L and C11R-R were double-digested with NdeⅠ and MluⅠ, and the two genes were connected using 2×Ligation highver.2. The connected products were transformed into competent DH5α, spread on LB solid plates containing ampicillin, cultured at 37°C for 10-16h, picked monoclonal plaques, transferred to liquid LB culture medium containing ampicillin, and cultured at 220rpm for 10-16h. Then, the recombinant vector pBAC11R-EGFP was extracted using a plasmid extraction kit.
[0121] 1.4.3 Obtain pBAC11R-mCherry
[0122] Design PCR primers for pBAC11R backbone and mCherry fragment,
[0123] The sequence of pBAC11R-L (SEQ ID NO: 16) is as follows: 5′-tagtcttttcaacgcctggcact-3′;
[0124] The sequence of pBAC11R-R (SEQ ID NO: 17) is as follows:
[0125] 5'-GTGAAGTGTCCCAGCCTGTTTAT-3'; mCherry-L (SEQ ID NO: 18) sequence is as follows:
[0126] 5'-aacaggctgggacacttcacataacttcgtatagcatacattatacgaagttatATGGTGAGCAAGG GCGAGGA-3';
[0127] The sequence of mCherry-R (SEQ ID NO: 19) is as follows:
[0128] 5'-gccaggcgttgaaaagactaCTACTTGTACAGCTCGTCCATGCC-3';
[0129] The pBAC11R backbone and mCherry sequences were obtained by high-fidelity PCR from pBAC11R-EGFP and pcDNA3.1-mCherry. The specific PCR reaction process is as follows:
[0130] High-fidelity PCR reaction system: KOD New buffer (5μL), 2mM dNTPs (5μL), 25mM MgSO4 (3μL), upstream primer (1.5μL), downstream primer (1.5μL), template (2μL), KOD enzyme (1μL), and ddH2O to make up the volume to 50μL.
[0131] PCR reaction program: pre-denaturation at 94°C for 2 min, denaturation at 98°C for 10 s, annealing at 56°C for 30 s, extension at 68°C for 30 s, and extension at 68°C for 7 min after 35 cycles.
[0132] 1% agarose gel electrophoresis was performed at 120V for 30 minutes, and the two PCR amplification products pBAC11R backbone and mCherry were recovered using a gel tapping recovery kit (Youkang Biological Product No.: YK00A2). The two gel tapping recovery products were connected according to the molar mass ratio of pBAC11R backbone: mCherry = 1:3 through a seamless cloning kit (Quanshijin, Product No.: CU101-01), 50°C for 15 minutes, and then the connection product was transformed into competent DH5α, coated on an LB solid plate containing ampicillin, and cultured at 37°C for 10-16 hours. The monoclonal plaque was picked and transferred to a liquid LB medium containing ampicillin, and shaken and cultured at 220rpm for 10-16 hours, and then the recombinant vector pBAC11R-mCherry was extracted using a plasmid extraction kit.
[0133] 1.5 Construction of plasmid px459-C11R-gRNA
[0134] 1.5.1 Synthesize C11R-gRNA;
[0135] The forward sequence of C11R-gRNA C11R gRNAF (SEQ ID NO: 20) was synthesized as follows: 5'-CACCGatcagattatgcggtccag-3'; the reverse sequence of C11R-gRNA B8R gRNAR (SEQ ID NO: 21) was synthesized as follows: 5'-AAACctggaccgcataatctgatC-3'.
[0136] The forward and reverse sequences of C11R-gRNA were annealed to form a double-stranded DNA structure. The annealing reaction program was: 90℃~100℃5~10min; 80℃~90℃5~10min, 70℃~80℃5~10min, 60℃~70℃5~10min, 50℃~60℃5~10min, 40℃~50℃5~10min, 30℃~40℃5~10min, 20℃~30℃5~10min, 10℃~20℃5~10min.
[0137] 1.5.2 Obtaining px459-C11R-gRNA
[0138] The pX459 plasmid was linearized using BbsI and the digestion product was dephosphorylated using the dephosphorylase Fast AP. The two genes were connected using 2×Ligation high ver.2 and the connected product was transformed into competent DH5α, spread on a solid LB plate containing ampicillin, cultured at 37°C for 10-16h, picked a monoclonal plaque, transferred to a liquid LB medium containing ampicillin, and cultured at 220rpm for 10-16h, and then the recombinant vector px459-C11R-gRNA was extracted using a plasmid extraction kit.
[0139] 1.6 Build and package VV-ΔV
[0140] 1.6.1 Obtaining VV-ΔV-mCherry
[0141] 2 μg of px459-C11R-gRNA plasmid extracted with endotoxin-free medium was diluted with PEI in a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, 6-well plate with fresh 10% FBS cell culture medium. Place in 37℃5%CO2 cell culture incubator, culture for 8h, discard the cell supernatant, replace with fresh 5% FBS cell culture medium, discard the cell supernatant after 24h, infect VV-WR oncolytic virus according to 1MOL thin layer, discard the virus liquid after 2h, extract 2μg pBAC11R-mCherry plasmid without endotoxin, dilute PEI with serum-free medium according to the mass ratio of plasmid: PEI = 1:3, and then slowly drip into the mixture of plasmid and serum-free medium, gently mix, and stand at room temperature for 15min. After standing, add the mixture to 6-well plate containing 3×105 / well HEK293A, 6-well plate with fresh 10% FBS cell culture medium. Place the cells in a 37°C 5% CO2 cell culture incubator. After culturing for 8 hours, discard the cell supernatant and replace with fresh 5% FBS cell culture medium. Continue culturing for 3 days and observe cell lesions and fluorescence. After lesions, collect the supernatant and cells to obtain the first-generation virus P1, i.e., oncolytic vaccinia virus VV-ΔV-mCherry.
[0142] 1.6.2 Obtaining VV-ΔV
[0143] 2 μg of pcDNA3.1-Cre-HA plasmid extracted with endotoxin-free medium was diluted with PEI in a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, fresh 10% FBS cell culture medium was added to the 6-well plate. Placed in a 37°C 5% CO2 cell culture incubator, after 8 hours of culture, the cell supernatant was discarded, replaced with fresh 5% FBS cell culture medium, discarded the cell supernatant after 24 hours, infected with VV-ΔV-mCherry oncolytic virus according to 1MOL thin layer, discarded the virus liquid after 2 hours, replaced with fresh 5% FBS cell culture medium, continued to culture for 3 days, observed cell lesions and fluorescence, after lesions, collected supernatant and cells, and obtained the first generation virus P1, i.e. oncolytic vaccinia virus VV-ΔV.
[0144] 1.7 Build and package VV-ΔT
[0145] 1.7.1 Obtaining VV-ΔT-EGFP
[0146] 2 μg of the px459-TK-gRNA plasmid extracted with endotoxin-free solution was diluted with PEI in a serum-free medium at a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, 6-well plate with fresh 10% FBS cell culture medium. Place in a 37 ° C 5% CO2 cell culture incubator, culture for 8 hours, discard the cell supernatant, replace with fresh 5% FBS cell culture medium, discard the cell supernatant after 24 hours, infect VV-WR oncolytic virus according to 1MOL thin layer, discard the virus liquid after 2 hours, extract 2μg of the above pBATK-EGFP plasmid without endotoxin, according to the mass ratio of plasmid: PEI = 1:3, dilute and mix PEI with serum-free medium, and then slowly drip into the mixture of plasmid and serum-free medium, gently mix, and stand at room temperature for 15 minutes. After standing, add the mixture to a 6-well plate containing 3×105 / well HEK293A, and add fresh 10% FBS cell culture medium to the 6-well plate. Place the cells in a 37°C 5% CO2 cell culture incubator. After culturing for 8 hours, discard the cell supernatant and replace with fresh 5% FBS cell culture medium. Continue culturing for 3 days to observe cell lesions and fluorescence. After lesions, collect the supernatant and cells to obtain the first-generation virus P1, i.e., oncolytic vaccinia virus VV-ΔT-EGFP.
[0147] 1.7.2 Obtaining VV-ΔT
[0148] 2 μg of pcDNA3.1-Cre-HA plasmid extracted with endotoxin-free medium was diluted with PEI in a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, fresh 10% FBS cell culture medium was added to the 6-well plate. Placed in a 37°C 5% CO2 cell culture incubator, after 8 hours of culture, the cell supernatant was discarded, and fresh 5% FBS cell culture medium was replaced. After 24 hours, the cell supernatant was discarded, and VV-ΔT-EGFP oncolytic virus was infected according to 1MOL thin layer. After 2 hours, the virus liquid was discarded, and fresh 5% FBS cell culture medium was replaced. The culture was continued for 3 days, and the cell lesions and fluorescence were observed. After the lesions, the supernatant and cells were collected to obtain the first generation virus P1, that is, oncolytic vaccinia virus VV-ΔT.
[0149] The construction results of oncolytic vaccinia virus single gene site deletion strains VV-ΔB, VV-ΔV, and VV-ΔT are shown in Figure 2 As shown, there was no wild-type strain contamination.
[0150] Example 2 Construction of oncolytic vaccinia virus double gene site deletion strains VV-ΔBV, VV-ΔTV, and VV-ΔTB
[0151] 2.1 Construction and packaging of VV-ΔBV
[0152] 2.1.1 Obtaining VV-ΔBV-mCherry
[0153] 2 μg of the px459-C11R-gRNA plasmid extracted with endotoxin-free solution was diluted with PEI in a serum-free medium at a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, 6-well plate with fresh 10% FBS cell culture medium. Place in a 37℃ 5% CO2 cell culture incubator, culture for 8 hours, discard the cell supernatant, replace with fresh 5% FBS cell culture medium, discard the cell supernatant after 24 hours, infect VV-ΔB oncolytic virus according to 1MOL thin layer, discard the virus liquid after 2 hours, extract 2μg of the above pBAC11R-mCherry plasmid without endotoxin, dilute and mix PEI with serum-free medium according to the mass ratio of plasmid: PEI = 1:3, and then slowly drip into the mixture of plasmid and serum-free medium, gently mix, and stand at room temperature for 15 minutes. After standing, add the mixture to a 6-well plate containing 3×105 / well HEK293A, and add fresh 10% FBS cell culture medium to the 6-well plate. Place the cells in a 37°C 5% CO2 cell culture incubator. After culturing for 8 hours, discard the cell supernatant and replace with fresh 5% FBS cell culture medium. Continue culturing for 3 days and observe cell lesions and fluorescence. After lesions, collect the supernatant and cells to obtain the first-generation virus P1, i.e., oncolytic vaccinia virus VV-ΔBV-mCherry.
[0154] 2.1.2 Obtaining VV-ΔBV
[0155] 2 μg of pcDNA3.1-Cre-HA plasmid extracted with endotoxin-free medium was diluted with PEI in a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, 6-well plate with fresh 10% FBS cell culture medium. Place in 37℃5% CO2 cell culture incubator, culture for 8 hours, discard the cell supernatant, replace with fresh 5% FBS cell culture medium, discard the cell supernatant after 24 hours, infect VV-ΔBV-mCherry oncolytic virus according to 1MOL thin layer, discard the virus liquid after 2 hours, replace with fresh 5% FBS cell culture medium, continue to culture for 3 days, observe cell lesions and fluorescence, collect supernatant and cells after lesions, and obtain the first generation virus P1, i.e. oncolytic vaccinia virus VV-ΔBV.
[0156] 2.2 Build and package VV-ΔTV
[0157] 2.2.1 Obtaining VV-ΔTV-EGFP
[0158] 2 μg of the px459-C11R-gRNA plasmid extracted with endotoxin-free solution was diluted with PEI in a serum-free medium at a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, 6-well plate with fresh 10% FBS cell culture medium. Place in a 37℃ 5% CO2 cell culture incubator, culture for 8 hours, discard the cell supernatant, replace with fresh 5% FBS cell culture medium, discard the cell supernatant after 24 hours, infect VV-ΔB oncolytic virus according to 1MOL thin layer, discard the virus liquid after 2 hours, extract 2μg of the above pBAC11R-EGFP plasmid without endotoxin, dilute and mix PEI with serum-free medium according to the mass ratio of plasmid: PEI = 1:3, and then slowly drip into the mixture of plasmid and serum-free medium, gently mix, and stand at room temperature for 15 minutes. After standing, add the mixture to a 6-well plate containing 3×105 / well HEK293A, and add fresh 10% FBS cell culture medium to the 6-well plate. Place the cells in a 37°C 5% CO2 cell culture incubator. After culturing for 8 hours, discard the cell supernatant and replace with fresh 5% FBS cell culture medium. Continue culturing for 3 days and observe cell lesions and fluorescence. After lesions, collect the supernatant and cells to obtain the first-generation virus P1, i.e., oncolytic vaccinia virus VV-ΔTV-EGFP.
[0159] 2.2.2 Obtaining VV-ΔTV
[0160] 2 μg of pcDNA3.1-Cre-HA plasmid extracted with endotoxin-free medium was diluted with PEI in a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, fresh 10% FBS cell culture medium was added to the 6-well plate. Placed in a 37°C 5% CO2 cell culture incubator, after 8 hours of culture, the cell supernatant was discarded, and fresh 5% FBS cell culture medium was replaced. After 24 hours, the cell supernatant was discarded, and VV-ΔTV-EGFP oncolytic virus was infected according to 1MOL thin layer. After 2 hours, the virus liquid was discarded, and fresh 5% FBS cell culture medium was replaced. The culture was continued for 3 days, and the cell lesions and fluorescence were observed. After the lesions, the supernatant and cells were collected to obtain the first generation virus P1, that is, oncolytic vaccinia virus VV-ΔTV.
[0161] 2.3 Construction and packaging of VV-ΔTB
[0162] 2.3.1 Obtaining VV-ΔTB-EGFP
[0163] 2 μg of the px459-B8R-gRNA plasmid extracted with endotoxin-free solution was diluted with PEI in a serum-free medium at a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, 6-well plate with fresh 10% FBS cell culture medium. Place in a 37℃ 5% CO2 cell culture incubator, culture for 8 hours, discard the cell supernatant, replace with fresh 5% FBS cell culture medium, discard the cell supernatant after 24 hours, infect VV-ΔB oncolytic virus according to 1MOL thin layer, discard the virus liquid after 2 hours, extract 2μg of the above pBAB8R-EGFP plasmid without endotoxin, dilute and mix PEI with serum-free medium according to the mass ratio of plasmid: PEI = 1:3, and then slowly drip into the mixture of plasmid and serum-free medium, gently mix, and stand at room temperature for 15 minutes. After standing, add the mixture to a 6-well plate containing 3×105 / well HEK293A, and add fresh 10% FBS cell culture medium to the 6-well plate. Place the cells in a 37°C 5% CO2 cell culture incubator. After culturing for 8 hours, discard the cell supernatant and replace with fresh 5% FBS cell culture medium. Continue culturing for 3 days to observe cell lesions and fluorescence. After lesions, collect the supernatant and cells to obtain the first-generation virus P1, i.e., oncolytic vaccinia virus VV-ΔTB-EGFP.
[0164] 2.3.2 Obtaining VV-ΔTB
[0165] 2 μg of pcDNA3.1-Cre-HA plasmid extracted with endotoxin-free medium was diluted with PEI in a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, 6-well plate with fresh 10% FBS cell culture medium. Place in 37℃5% CO2 cell culture incubator, culture for 8 hours, discard the cell supernatant, replace with fresh 5% FBS cell culture medium, discard the cell supernatant after 24 hours, infect VV-ΔTB-EGFP oncolytic virus according to 1MOL thin layer, discard the virus liquid after 2 hours, replace with fresh 5% FBS cell culture medium, continue to culture for 3 days, observe cell lesions and fluorescence, collect supernatant and cells after lesions, and obtain the first generation virus P1, i.e. oncolytic vaccinia virus VV-ΔTB.
[0166] The construction results of oncolytic vaccinia virus double gene site deletion strains VV-ΔBV, VV-ΔTV, and VV-ΔTB are shown in Figure 3 As shown, there was no wild-type strain contamination.
[0167] Example 3 Construction of oncolytic vaccinia virus triple gene site deletion strain VV-ΔBVT
[0168] 3.1 Construction and packaging of VV-ΔBVT
[0169] 3.1.1 Obtaining VV-ΔBVT-EGFP-mCherry
[0170] 2 μg of the px459-TK-gRNA plasmid extracted with endotoxin-free solution was diluted with PEI in a serum-free medium at a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, 6-well plate with fresh 10% FBS cell culture medium. Place in a 37℃ 5% CO2 cell culture incubator, culture for 8 hours, discard the cell supernatant, replace with fresh 5% FBS cell culture medium, discard the cell supernatant after 24 hours, infect VV-ΔB oncolytic virus according to 1MOL thin layer, discard the virus liquid after 2 hours, extract 2μg of the above pBATK-EGFP plasmid without endotoxin, dilute and mix PEI with serum-free medium according to the mass ratio of plasmid: PEI = 1:3, and then slowly drip into the mixture of plasmid and serum-free medium, gently mix, and stand at room temperature for 15 minutes. After standing, add the mixture to a 6-well plate containing 3×105 / well HEK293A, and add fresh 10% FBS cell culture medium to the 6-well plate. Place the cells in a 37°C 5% CO2 cell culture incubator. After culturing for 8 hours, discard the cell supernatant and replace with fresh 5% FBS cell culture medium. Continue culturing for 3 days and observe cell lesions and fluorescence. After lesions, collect the supernatant and cells to obtain the first-generation virus P1, i.e., oncolytic vaccinia virus VV-ΔBVT-EGFP-mCherry.
[0171] 3.1.2 Obtaining VV-ΔBVT
[0172] 2 μg of pcDNA3.1-Cre-HA plasmid extracted with endotoxin-free medium was diluted with PEI in a mass ratio of plasmid: PEI = 1:3, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, 6-well plate with fresh 10% FBS cell culture medium. Place in 37℃5% CO2 cell culture incubator, culture for 8 hours, discard the cell supernatant, replace with fresh 5% FBS cell culture medium, discard the cell supernatant after 24 hours, infect with VV-ΔBVT-EGFP-mCherry oncolytic virus according to 1MOL thin layer, discard the virus liquid after 2 hours, replace with fresh 5% FBS cell culture medium, continue to culture for 3 days, observe cell lesions and fluorescence, collect supernatant and cells after lesions, and obtain the first generation virus P1, i.e. oncolytic vaccinia virus VV-ΔBVT.
[0173] The construction results of the oncolytic vaccinia virus triple gene site deletion strains VV-ΔBV, VV-ΔTV, and VV-ΔTB are shown in Figure 4 As shown, there was no wild-type strain contamination.
[0174] Example 4 Screening of recombinant oncolytic vaccinia viruses and identification of wild-type viruses
[0175] The first generation virus was repeatedly frozen and thawed at -80℃ / 37℃ for three times, and then thin-layer infected HEK293A was amplified and fluorescently screened. 3×10 5 HEK293A cell line was plated on a six-well plate / well. Virus P1 was diluted 500, 1000, and 2000 times, and then added to the six-well plate in a thin layer at 700 μl / well for infection. After 2 hours, the virus solution was discarded, 3 ml of low-melting point glue was added, and the solution was placed in the incubator after it was completely solidified.
[0176] Preparation method of low-melting point gel: weigh 1g of low-melting point agarose gel in a 50mL centrifuge tube, add 20mL PBS, sterilize under high pressure and place at 4℃ for later use. 5% low-melting point gel: complete culture medium = 1:3. The first preparation of 5% low-melting point gel needs to be sterilized. It needs to be placed in an 80℃ water bath 1h in advance before subsequent use. The complete culture medium needs to be placed at 37℃ for 30 minutes in advance. After the temperature of 5% low-melting point gel and complete culture medium is suitable, add 5% low-melting point gel to the complete culture medium, mix it upside down, and add 3ml / well to the six-well plate. Observe the cell state 24, 48, and 72h after the thin layer, and use a fluorescence microscope to observe whether there are fluorescent labeled plaques and mark them. After 72h, use a gun tip to select fluorescent plaques, add 700μl FBSDMEM without FBSDMEM, and quickly freeze and thaw three times at 37℃ and liquid nitrogen to release the virus in the cells. Place it at -80 degrees Celsius for use, which is recorded as P1 virus liquid. The P2 virus solution was screened 3-4 times repeatedly to obtain a monoclonal oncolytic vaccinia virus strain.
[0177] A certain amount of virus liquid was taken and the recombinant oncolytic adenovirus genome was extracted using a DNA virus genome extraction kit (Solebo, catalog number: D2400). The virus genome was PCR-generated using TK, VGF, and B8R primers, and positive controls and experimental groups were set up for observation by agarose gel electrophoresis.
[0178] Example 5 Effect of Gene Site-Deleted Oncolytic Vaccinia Virus on the Growth of Tumor Cell Lines
[0179] 5.1 MTT assay to detect cell survival rate of tumor cell lines after virus infection
[0180] 5.1.1 MTT assay
[0181] At the sampling time point, 20 μL MTT (5 mg / mL) was added to each well of the cell culture plate. After incubation in the cell culture incubator for 4 h, the cell supernatant was aspirated, 150 μL DMSO was added to each well, and after mixing on a shaker for 10 min, the OD value was measured at 490 nm on a microplate reader, and the cell survival rate was calculated based on the OD value. The specific formula is as follows: Cell survival rate (%) = (OD of virus-infected well-OD of blank well) / (OD of control well-OD of blank well) × 100%.
[0182] 5.1.2 Cell viability detection of tumor cell lines
[0183] Pancreatic cancer cell lines SW1990 and PANC-1, colon cancer cell line SW480, lung cancer cell lines A549 and NCL-H460, liver cancer cell lines Hep3B and SMMC-7721 were used as experimental cell lines, and each cell line was plated in a 96-well plate (3000 / well, 100 μL / well). After the cells adhered to the wall, 1 MOL of the recombinant oncolytic vaccinia virus deletion vaccinia virus strain was added to the 96-well plate, and 3 replicates were set for each MOL group. Then, samples were taken at 6h, 24h, 48h, 72h, and 96h to determine the cell survival rate of each cell line. The results are shown in Figure 5-11 .
[0184] Depend on Figure 5-11 It can be seen that compared with the VV-WR strain, the single-site deletion strain has no significant change in tumor inhibitory ability against pancreatic cancer, colon cancer, lung cancer, and liver cancer cells. Figure 12-18 It can be seen that compared with the VV-WR strain, the double-site deletion strain had no significant changes in tumor inhibition ability against pancreatic cancer, colon cancer, lung cancer, and liver cancer cells. The triple-site deletion strain had a significant inhibitory effect on pancreatic cancer, colon cancer, and lung cancer cells, but had no significant inhibitory ability on liver cancer cell lines.
[0185] Example 6 Detection of the replication ability of progeny of three-site deletion strains of vaccinia virus
[0186] 6.1 qPCR method to detect oncolytic vaccinia virus titer
[0187] After the virus was repeatedly frozen and thawed three times at -80°C / 37°C, a certain amount of virus liquid was taken to extract the recombinant oncolytic adenovirus genome using a DNA virus genome extraction kit (Solebo, catalog number: D2400). The standard curve was prepared using the VV-WR strain genome, MW (VV) = 194711x660 = 128509260Da, the copy number of the standard DNA was calculated according to the formula, and then diluted with ddH2O to 1x107, 1x106, 1x105, 1x104, copies / μL, the relationship between CT value and log (copy number): y = a + bx. The vaccinia virus genome was used to detect the three-point deletion virus genome using primers qPCR.
[0188] Depend on Figure 19-20 It can be seen that compared with the VV-WR group, the progeny titer of the VV-ΔBVT strain was not significantly different from that of the VV-WR group, indicating that the progeny replication time of the VV-ΔBVT strain in colon cancer cells increased while the number of progeny increased.
[0189] Example 7 Verification of the sensitivity of vaccinia virus VV-ΔBVT to IFN-γ in colon cancer cells
[0190] In the vaccinia virus genome, the B8R site gene is expressed as an IFN-γ receptor protein to resist the antiviral effect of IFN-γ. In order to verify whether the sensitivity of the VV-ΔBVT-EC strain with the B8R site knocked out to IFN-γ in colon cancer cells has changed, IFNγ and VV-ΔBVT strains were added to SW480 cells at the same time. The clinical index of IFN-γ in human blood is 1.21-5.51pg / μl. In this experiment, the IFN-γ concentration was increased from 500pg / μl, and 1MOL of VV-ΔBVT strain was added. The cell viability was detected after 72 hours to determine whether IFN-γ affects the ability of the VV-ΔBVT strain to kill cancer cells. The results are as follows Fig.21 In SW480 cells, the effect of IFN-γ was weak, and the cell killing ability of the VV-ΔBVT strain was significantly reduced, but it still had similar cell killing ability to the VV-WR strain and could effectively kill colon cancer cells.
[0191] Finally, it should be noted that the present invention is not limited to the above embodiments, and there are many variations. All variations that can be directly derived or associated with the content disclosed by ordinary technicians in this field should be considered as the protection scope of the present invention.
Claims
1. A method for constructing, packaging and screening a recombinant oncolytic vaccinia virus carrying a fluorescent gene and a loxp-CRE system, characterized in that: The following steps are involved: Step 1): constructing a plasmid pBATK-EGFP carrying the EGFP gene, wherein the plasmid pBATK-EGFP is a de novo constructed plasmid, which uses the Western Reverse strain of vaccinia virus as a backbone and uses EGFP as a screening marker; Step 2): construct a plasmid pX459-TK-gRNA carrying a TK-gRNA sequence, wherein the plasmid pX459-TK-gRNA uses a CRISPR / Cas9 plasmid as a template and carries a gRNA targeting the TK gene of the vaccinia virus genome; construct a plasmid px459-C11R-gRNA carrying a VGF gene C11R-gRNA sequence; construct a plasmid px459-B8R-gRNA carrying an IFN-γ gene B8R-gRNA sequence; Step 3): constructing a plasmid pcDNA3.1-loxp-CRE carrying a loxp-CRE sequence, wherein the plasmid pcDNA3.1-loxp-CRE is based on pcDNA3.1 and has a loxp site and a CRE enzyme gene sequence inserted therein; Step 4): Plasmid px459-TK-gRNA and plasmid pBATK-EGFP were transfected into HEK293A cells and infected with VV-WR oncolytic vaccinia virus, and after packaging, the recombinant oncolytic vaccinia virus VV-ΔT-EGFP carrying the EGFP gene and the TK gene was deleted, the recombinant oncolytic vaccinia virus VV-ΔV-EGFP carrying the EGFP gene and the C11R gene was deleted, and the recombinant oncolytic vaccinia virus VV-ΔB-EGFP carrying the EGFP gene and the B8R gene was deleted was obtained respectively; Step 5): transfecting the pCDNA3.1-loxp-CRE described in step 3) into HEK293A cells, and infecting VV-ΔT-EGFP, VV-ΔV-EGFP or VV-ΔB-EGFP oncolytic vaccinia virus, and packaging to obtain recombinant oncolytic vaccinia viruses VV-ΔT, VV-ΔV and VV-ΔB in which the EGFP gene is deleted and the TK gene is deleted; Step 6): using the recombinant oncolytic vaccinia viruses VV-ΔT, VV-ΔV and VV-ΔB obtained in step 5) as the base viruses, respectively, steps 4) and 5) are repeated to obtain dual-targeted recombinant oncolytic vaccinia viruses VV-ΔTV, VV-ΔVB and VV-ΔTB that simultaneously lack TK and VGF, simultaneously lack TK and B8R, and simultaneously lack VGF and B8R; Step 7): Using the dual-targeted recombinant oncolytic vaccinia virus VV-ΔTV obtained in step 6) as the base virus, repeat the transfection of px459-B8R-gRNA and pCDNA3.1-loxp-CRE in steps 4) and 5) to obtain the triple-targeted recombinant oncolytic vaccinia virus VV-ΔTVB.
2. A method for constructing and packaging a recombinant oncolytic vaccinia virus carrying a fluorescent gene and a loxp-CRE system according to claim 1, characterized in that: The step 1) comprises the following sub-steps: Step 1-1): Perform high-assurance PCR on pCB023-Ⅱ to amplify pCB-backbone; Step 1-2): Perform high-quality PCR on pcDNA3.1-EGFP to amplify loxp EGFP; Step 1-3): seamlessly clone the pCB-backbone and loxp EGFP to obtain the pBATK-EGFP.
3. The method for constructing and packaging a recombinant oncolytic vaccinia virus carrying a fluorescent gene and a loxp-CRE system according to claim 1, characterized in that: The step 2) comprises the following sub-steps: Step 2-1): synthesizing TK-gRNA; Step 2-2): Connect the TK-gRNA to px459 to obtain px459-TK-gRNA.
4. The method for constructing, packaging and screening a recombinant oncolytic vaccinia virus carrying a fluorescent gene and a loxp-CRE system according to claim 1, characterized in that: The step 3) comprises the following sub-steps: Step 3-1): synthesizing Cre-HA; Step 3-2): Connect the Cre-HA to pcDNA3.1 to obtain pcDNA3.1-Cre-HA.
5. The method for constructing, packaging and screening a recombinant oncolytic vaccinia virus carrying a fluorescent gene and a loxp-CRE system according to claim 1, characterized in that: The step 4) comprises the following sub-steps: Step 4-1): transfect px459-TK-gRNA into HEK293A cells; Step 4-2): Infect the HEK293A cells described in step 4-1) with VV-WR oncolytic vaccinia virus; Step 4-3): Transfect pBATK-EGFP into the HEK293A cells described in step 4-2), and obtain VV-ΔT-EGFP after culture.
6. The method for constructing, packaging and screening a recombinant oncolytic vaccinia virus carrying a fluorescent gene and a loxp-CRE system according to claim 1, characterized in that: The step 5) comprises the following sub-steps: Step 5-1): transfect pcDNA3.1-Cre-HA into HEK293A cells; Step 5-2): The HEK293A cells in step 5-1) were infected with VV-ΔT-EGFP, VV-ΔV-EGFP or VV-ΔB-EGFP oncolytic vaccinia virus, and after culture, single-targeted oncolytic vaccinia viruses VV-ΔT, VV-ΔV or VV-ΔB, dual-targeted recombinant oncolytic vaccinia viruses VV-ΔTV, VV-ΔVB, VV-ΔTB and triple-targeted recombinant oncolytic vaccinia virus VV-ΔTVB were obtained.
7. The use of a fluorescent gene and loxp-CRE system for constructing, packaging and screening a recombinant oncolytic vaccinia virus according to any one of claims 1 to 6, characterized in that: Applied to products, including drugs, pharmaceutical raw materials or targeted inhibitors.
8. The use according to claim 7, characterized in that: The medicament includes an oncolytic vaccinia virus vaccine.
9. The use according to claim 8, characterized in that: The drug also includes pharmaceutically acceptable excipients.
10. The use according to claim 9, characterized in that: The auxiliary material may be one or more of an osmotic pressure regulator, a lyophilization protectant, a surfactant, a buffer, and an excipient.
